Detail akcie Simulatns Plus online

Business Summary: Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
Financial Summary: BRIEF: For the six months ended 29 February 2024, Simulations Plus Inc revenues increased 18% to $32.8M. Net income increased 10% to $6M. Revenues reflect Software segment increase of 16% to $19.2M, Services segment increase of 22% to $13.6M, Americas segment increase of 22% to $23.4M, Europe segment increase of 21% to $7M. Net income was partially offset by Change in fair valuation of contingent c increase from $0K to $330K (expense).